With only 3.3% of non-contributive test results, shallowHRDv2 robustness is similar to other genetic testing in clinical routine, such as BRCA1/2 tumor mutation testing, which showed a 4.4% failure rate in the PAOLA-1 clinical trial [20]. Here, BRCA1 is linked to neoplasm.